Friday, September 22, 2023
Clinical Advances in
Hemophilia is a chronic, complex disorder that has serious, potentially life-threatening complications and requires lifelong management. While the life expectancy of patients with hemophilia has dramatically increased over the past several decades, the hemophilia population still faces unique challenges that require appropriate use of effective strategies for prophylaxis and episodic treatment. This educational initiative presents current and emerging approaches for overcoming barriers to the optimal management of patients with hemophilia.
Supported by an independent educational grant from
Bioverativ Therapeutics
Presented through a collaboration between the National Hemophilia Foundation and Medscape.
Prophylaxis Versus Episodic Treatment to Prevent Joint Disease in Boys With Severe Hemophilia Read article
Guidelines for the Management of Hemophilia Read article
Randomized, Controlled, Parallel-Group Trial of Routine Prophylaxis Versus On-Demand Treatment With Rfviii-FS in Adults With Severe Hemophilia A (SPINART) Read article
See All
Steering Committee Chair
Professor of Pediatrics and Pathology, University of Michigan, Ann Arbor, Michigan
Department of Pediatrics, Gulf States Hemophilia & Thrombophilia Center, Houston, Texas
Associate Professor, Departments of Pediatrics and Hematology and Medical Oncology, Director's Chair in Hemostasis Aflac Cancer and Blood Disorders Center, Emory University School of Medicine, Atlanta, Georgia
Professor of Medicine and Pathology; Director, Division of Coagulation, Hemophilia and Thrombosis Comprehensive Care Center, Georgetown University Medical Center, Washington, DC
Angelo Bianchi Bonomi Hemophilia and Thrombosis Center Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Department of Pathophysiology and Transplantation Università degli Studi di Milano Milan, Italy
Nurse Practitioner, Northern Regional Bleeding Disorders Center at Madison Medical Center, Traverse City, Michigan
Steering Committee Chair
Has disclosed the following relevant financial relationships
Served as an advisor or consultant for: Baxter; Biogen Idec Inc.; Chatham Therapeutics LLC; CSL Behring; Novo Nordisk; Pfizer Inc
Received grants for clinical research from: Pfizer Inc
Has disclosed the following relevant financial relationships
Received grants for clinical research from: Baxalta; Shire
Has disclosed the following relevant financial relationships
Served as an advisor or consultant for: Bayer HealthCare Pharmaceuticals; Baxter; CSL Behring
The opinions expressed are those of Dr Kempton and do not necessarily reflect the views of Emory University or Emory Healthcare. Dr Kempton's participation as a member of this steering committee does not constitute or imply endorsement by Emory University or Emory Healthcare.
Has disclosed the following relevant financial relationships
Served as an advisor or consultant for: Alnylam Pharmaceuticals, Inc.; Baxter; Bayer HealthCare Pharmaceuticals; Biogen Idec Inc.; Genentech, Inc.; Grifols; Novo Nordisk; Octapharma; Pfizer Inc
Served as a speaker or a member of a speakers bureau for: Baxter; Biogen Idec Inc.; Grifols; Novo Nordisk; Octapharma; Pfizer Inc
Received grants for clinical research from: Baxter; Biogen Idec Inc.; Grifols; Novo Nordisk; Octapharma
Has disclosed the following relevant financial relationships
Served as an advisor or consultant for: Bayer HealthCare Pharmaceuticals; CSL Behring; Novo Nordisk
Has disclosed the following relevant financial relationships
Served as an advisor or consultant for: Baxalta; Biogen Idec Inc.; Emergent BioSolutions; Novo Nordisk; Octapharma; Pfizer Inc.
Served as a speaker or a member of a speakers bureau for: Novo Nordisk; Pfizer Inc.; Emergent BioSolutions
Received grants for clinical research from: Pfizer Inc.